Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?

VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.